The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.
Cano Health’s downfall offers a warning for Medicare Advantage
Private Medicare just isn’t the gold mine it once was. Case in point: Cano Health, a company once valued at $4.4 billion, is now bankrupt.
February 5, 2024